Clarivate Plc Q4 2025 Earnings Call Summary

Management characterizes 2025 as a positive inflection point, marking the first time since 2019 that the company delivered on its initial full-year financial guidance. The decision to sell the Life Sciences & Health (LS&H) business is intended to sharpen focus on the Academia & Government (A&G) and Intellectual Property (IP) segments while aggressively deleveraging the balance sheet. Performance attribution for the year includes a 90 basis point improvement in organic ACV growth, driven by enhanced sa ...